Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: Improved pharmacokinetics and biodistribution in tumor-bearing mice

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 1196-1205

  Wang, Xianhuo ^a   Deng, Linyu ^a   Chen, Xiang ^a   Pei, Heying ^a   Cai, Lulu ^a   Zhao, Xia ^a   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cationic liposomes; Distribution; Drug targeting; Liposomes; Paclitaxel; Pharmacokinetics; Targeted drug delivery; Truncated basic fibroblast growth factor; Tumor; Tumor targeted delivery system

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; LIPOSOME; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; FEMALE; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

EID: 79251557799     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22348     Document Type: Article

References (29)

1. Harrington KJ, Lewanski CR, Stewart JSW. 2000. Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development. Clin Oncol (R Coll Radiol) 12:2-15.
2. Harrington KJ, Lewanski CR, Stewart JSW. 2000. Liposomes as vehicles for targeted therapy of cancer. Part 2: Clinical development. Clin Oncol (R Coll Radiol) 12:16-24.
3. Rahman A, Carmichael D, Harris M, Roh JK. 1986. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 46:2295-2299.
4. Ferrari M. 2005. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 5:161-171.
5. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. 2004. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 110:117-124.
6. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. 1998. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101:1401-1413.
7. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL. 2002. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831-6836.
8. Coulier F, Pontarotti P, Roubin R, Hartung H, Goldfarb M, Birnbaum D. 1997. Of worms and men: An evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol 44:43-56.
9. Powers CJ, McLeskey SW, Wellstein A. 2007. Fibroblast growth factors, their receptors and signaling. Endocr-Relat Cancer 7:165-197.
10. Terada T, Mizobata M, Kawakami S, Yamashita F, Hashida M. 2007. Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release 119:262-270.
11. Danielsen T, Rofstad EK. 1998. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer 76:836-841.
12. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D, de Lapeyriere O. 1995. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61:170-176.
13. Kwabi-Addo B, Ozen M, Ittmann M. 2004. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr-Relat Cancer 11:709-724.
14. Kinsella L, Chen HL, Smith JA, Rudland PS, Fernig DG. 1988. Interactions of putative heparin-binding domains of basic fibroblast growth factor and its receptor, FGFR-1, with heparin using synthetic peptides. Glycoconj J 15:419-422.
15. Terada T, Mizobata M, Kawakami S, Yabe Y, Yamashita F, Hashida M. 2006. Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target 14:536-545.
16. Caplen NJ. 2000. Nucleic acid transfer using cationic lipids. Methods Mol Biol 133:1-19.
17. Dalkara D, Chandrashekhar C, Zuber G. 2006. Intracellular protein delivery with a dimerizable amphiphile for improved complex stability and prolonged protein release in the cytoplasm of adherent cell lines. J Control Release 116:353-359.
18. Lonez C, Vandenbranden M, Ruysschaert JM. 2008. Cationic liposomal lipids: From gene carriers to cell signaling. Prog Lipid Res 47:340-347.
19. Chen X, Wang XH, Wang YS, Yang L, Hu J, Xiao WJ, Fu AF, Cai LL, Li X, Ye X, Liu YL, Wu WS, Shao XM, Mao YQ, Wei YQ, Chen LJ. 2010. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. doi: 10.1016/j.jconrel.2010.03.007.
20. ten Tije AJ, Smorenburg CH, Seynaeve C, Sparreboom A, Schothorst KLC, Kerkhofs LGM, van Reisen LGPM, Stoter G, Bontenbal M, Verweij J. 2004. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer: A multicentre phase II trial. Eur J Cancer 40:352-357.
21. Thomas H, Rosenberg P. 2002. Role of weekly paclitaxel in the treatment of advanced overian cancer. Crit Rev Oncol Hemat 44:43-51.
22. Meier F, Guenova E, Clasen S, Eigentler T, Forschner A, Leiter U, Zielinski C, Knaudt B, Garbe C, Berneburg M. 2009. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 60:863-868.
23. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. 2003. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9(6):2335-2341.
24. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M. 2008. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 122:452-460.
25. Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. 2005. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther 4(4):625-631.
26. Kim SI, Kim KS, Kim HS, Kim DS, Jang Y, Chung KH, Park YS. 2003. Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors. Cancer Res 63:6458-6462.
27. Du SL, Pan H, Lu WY, Wang J, Wu J, Wang JY. 2007. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 322:560-568.
28. Drummond D, Meyer O, Hong K, Kirpotin D, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
29. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. 2003. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105:561-567.